Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 5

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 3
Chunk 5
---
 candidates that we or our subsidiaries may develop and market may be later withdrawn from the market or subject
                                                          to promotional limitations.                                                       
--------------------------------------------------------------------------------------------------------------------------------------------

●                                             Healthcare                                          
    reform measures and other statutory or regulatory changes could adversely affect our business.
--------------------------------------------------------------------------------------------------

●                                            We                                         
    could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act.
----------------------------------------------------------------------------------------

2

Risks Related to Intellectual Property

●                                                                     Our                                                                  
    success depends upon our ability to protect our intellectual property and our proprietary technology, to operate without infringing the
                   proprietary rights of third parties and to obtain marketing exclusivity for our products and technologies.              
-------------------------------------------------------------------------------------------------------------------------------------------

●                                                                          We                                                                      
    may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual
                                                        property rights in those jurisdictions.                                                    
---------------------------------------------------------------------------------------------------------------------------------------------------

●                                      Intellectual                                   
    property rights do not address all potential threats to our competitive advantage.
--------------------------------------------------------------------------------------

●                                                                  Changes                                                               
    in patent laws or patent jurisprudence could diminish the value of our patents, thereby impairing our ability to protect our products
                                                            or product candidates.                                                       
-----------------------------------------------------------------------------------------------------------------------------------------

●                                                                  Confidentiality                                                                
    agreements with employees and others may not adequately prevent disclosure of our trade secrets and protect our other proprietary information.
--------------------------------------------------------------------------------------------------------------------------------------------------

Risks Related to Our Compliance with the Sarbanes-Oxley Act of 2002

●                                                                       We                                                                   
       may fail to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of  
    2002, which could adversely affect our operating results, investor confidence in our reported financial information, and the market price
                                                         of our ordinary shares and ADSs.                                                    
---------------------------------------------------------------------------------------------------------------------------------------------

●                                                        Material                                                    
    weaknesses in our disclosure controls and procedures could negatively affect shareholder and customer confidence.
---------------------------------------------------------------------------------------------------------------------
Risks Related to Ownership of Our Securities

●                                          Our                                        
    stock price may be volatile and the trading markets for our securities is limited.
--------------------------------------------------------------------------------------

●                                        Ownership                                      
    interest in our company may be further diluted as a result of additional financings.
----------------------------------------------------------------------------------------

●                                                                     There                                                                   
    is a substantial risk that we are a passive foreign investment company, or PFIC, to some U.S. investors which will subject those investors
                                                               to adverse tax rules                                                           
----------------------------------------------------------------------------------------------------------------------------------------------

●                               We                            
    do not anticipate paying dividends on our ordinary shares.
--------------------------------------------------------------

●                              Currency